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DIRECT COSTS OF PNEUMONIA IN THE UNITED STATES: AN ANALYSIS OF 2008
MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Parkv H, Rascati KL
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To estimate annual health care utilization and costs of pneumonia
across age cohorts in the United State (US) from an all-payer perspective.
METHODS: A retrospective cross-sectional study was conducted using the 2008
Medical Expenditure Panel Survey (MEPS) database, a nationally representative
annual survey of the civilian non-institutionalized population of the US. Pneu-
monia patients were identified as those with a Clinical Classification Code for
pneumonia (code with 122). Resources used and expenditures incurred by pa-
tients with pneumonia that were directly attributable to pneumonia treatment
(physician office visits, emergency room visits, outpatients visits, inpatient vis-
its, other medical visits, and medications) were estimated. Health care costs per
year per person (PYPP) were assessed across five age cohorts (5, 5-18, 18-50,
50-64, and 65 years old) and reported in 2008 US dollars. RESULTS: A total of
297 patients (representing 3.1 million persons) reported using medical re-
sources or incurring expenditures due to pneumonia. Direct medical costs at-
tributable to pneumonia were estimated at $2,763 (standard error [SE] 344) per
patient. Approximately 86% ($2,394) of this estimate was generated by inpatient
hospitalizations for pneumonia, which were experienced by 26.9% of pneumo-
nia patients, with an average of 0.31 admissions per patient. Physician office
visits and home health visits were the next largest categories of expenditure,
contributing $153 (5.5%) and $113 (4.1%), respectively. By age cohort, mean at-
tributable costs PYPP for patients 5 (n47), 5-18 (n38), 18-50 (n41), 50-
64 (n108), and 65 years old (n63) were $2,166 (1043), $579 (119), $1,747
($888), $2,983 (556), and $4,201 (553), respectively (p 0.05). CONCLUSIONS:
This study provides an overview of clinical and economic burden of pneumonia
in the US. Pneumonia-attributable expenditures were considerable, strongly
driven by high inpatient hospitalization cost. In addition, patients aged  65
years had highest expenditures of pneumonia among all age cohort.
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TRENDS IN UK SMOKING CESSATION PRESCRIPTION EXPENDITURE OVER
TIME - A THIN DATABASE STUDY
Blak BT, Lee J, Dungarwalla M
Cegedim Strategic Data Medical Research Ltd, London, UK
OBJECTIVES: In the UK, smoking cessation prescriptions (SCPs) include bupro-
pion, nicotine replacement therapy (NRT) and varenicline, where NRT and bu-
propion were available around 2000 and varenicline in 2006, with NRT being
relatively less expensive. This study evaluates the trends in SCP expenditure
from the national payer perspective. METHODS: From patients 18 years, an-
nual SCPs were obtained between January 1, 2000 - December 31, 2009 from The
Health Improvement Network (THIN) database, which holds anonymised longi-
tudinal UK primary care data from 500 practices. Drug prices came from the
British National Formulary March 2010 to estimate real growth in expenditure.
Expenditure trends were disaggregated by prescription frequency; treatment
prevalence, defined as the number of patients receiving a SCP in THIN; SCPs per
patient treated; and average drug expenditure per SCP. Sensitivity of 5% was
applied towards expenditure. RESULTS: Total number of SCPs was 9,706 in 2000
and estimated 131,466 in 2009. SCP expenditure were estimated at 7,416,741£
(range:7,045,904-£;7,787,578£) in 2000 (2010 £ values) and 77,904,026£ in 2009
(range:74,008,825-£; 81,799,228£) reflecting a 950.4% real rate of increase. Bupro-
pion prescription frequency was 70.8% in 2000 decreasing to 2.2% in 2009, NRT
frequency was 29.2% in 2000 peaking at 94.4% in 2006 and declining to 65.1% in
2009, and varenicline frequency was 16.8% in 2007 increasing to 32.8% in 2009.
Treatment prevalence rose from 0.3% in 2000 to 2.0% in 2009, while the average
annual SCPs per patient treated increased from 1.5 to 3.0. The average SCP
expenditure per SCP decreased to 22.2£ in 2006, however increased to 25.8£ in
2009. CONCLUSIONS: The expenditure increase reflects increase in treatment
prevalence and average annual SCPs per patient treated. Furthermore, the in-
troduction of varenicline may have impacted recent expenditures as the aver-
age SCP expenditure per SCP increased at varenicline introduction, suggesting a
product shift towards more expensive SCPs.
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ADHERENCE TO CURRENT GUIDELINES FOR CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD) IN SUBJECTS TREATED WITH COMBINATION
OF LONG-ACTING 2-AGONIST (LABA), LONG-ACTING MUSCARINIC
ANTAGONIST (LAMA) OR INHALED CORTICOSTEROIDS (ICS)
Asche C1, Leader S2, Plauschinat C3, Raparla S4, Ye X4, Yan M4, Young D4
1University of Illinois College of Medicine, Peoria, IL, USA, 2Novartis, East Hanover, NJ, USA,
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4University of Utah College of
Pharmacy, Salt Lake City, UT, USA
OBJECTIVES:To estimate the potential cost savings and reduction in exacerbations
by following guideline recommendations in subjects being treated for COPD with
the combination of LABA, LAMA or ICS. METHODS: Subjects were identified with a
diagnosis for COPD using ICD-9 codes between January 1, 2004 to December 31,
2007. The index date was based on first prescription of a LAMALABA,
LAMALABA/ICS, or LABAICS. Based on pulmonary function test (PFT) data
within 30 days of the index date, subjects were classified as adhering or non-
adhering to guidelines. Chi-square and t-test were conducted to determine the
differences among cohorts. RESULTS: A total of 365 subjects were identified as
adhering or non-adherent to guidelines based on their PFT data. Oxygen were
significantly higher in LAMA plus LABA/ICS and lower in LABA/ICS as compared to
LAMA plus LABA cohort (p0.05). Also, number of office visits and hospital admis-
sions were significantly higher in LAMA plus LABA/ICS compared to LAMA plus
LABA cohort. The mean number of prescriptions for antibiotics and prednisone
was higher in LAMA plus LABA/ICS cohort. The highest mean number of baseline
exacerbations was observed in LAMA plus LABA/ICS group (12.9) with 6.06 in LABA
plus ICS group and 7.76 in LAMA plus LABA group. 31% of the subgroup received
COPD medications consistent with guidelines was associated with cost savings of
$5,889 for LAMA plus LABA, $3,330 for LABAICS, and $10,217 for LAMA plus LABA/
ICS cohorts. The LAMA plus LABA (1.3 vs. 2.9) LABA plus ICS (2.78 vs. 3.57), and
LAMA plus LABA/ICS (-0.82 vs. 3.62) cohorts had lower mean change in exacerba-
tions in adhering group versus non-adhering group. CONCLUSIONS: Adherence to
current GOLD guidelines is associated with lower costs and fewer exacerbations in
subjects with moderate to severe COPD for LAMA plus LABA, LABA plus ICS and
LAMA plus LABA/ICS groups. AbstractsAbstracts
PRS29 EVALUATION OF STABLE COPD MEDICATION COSTS IN UKRAINE BASED
ON GPS’ PRESCRIPTIONS HABITS SURVEY RESULTS
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1O.O. Bohomolets National Medical University, Kyiv, Ukraine, 2Danylo Halytsky Lviv National
Medical University, Lviv, Ukraine
OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of
chronic morbidity and mortality throughout the world. There was not any reliable
information about its prevalence, morbidity and mortality in Ukraine until 2009.
METHODS: We analyzed the data about COPD from the first report of Ukrainian
Center of Medical Statistics. Than we calculated, the number of COPD cases needed
the basis in 2009 and the approximate costs for COPD basis therapy based on data
from the survey of Ukrainian GP’s prescription habits in treatment of stable COPD.
RESULTS: According to the Ukrainian Center’s of Medical Statistics data in 2009
prevalence of COPD in Ukraine amounted to 998.7 per 100,000 (377,267 persons),
morbidity – 79.2 per 100,000 (29,928 persons), mortality – 29.5 per 100,000 (11,121
persons). The number of persons with COPD needed the basis were 336,218 (total
number of cases excluding new patients and deaths). According to our survey of
Ukrainian GP’s prescription habits for stable COPD basis 56.8% of COPD patients
were given by fenoterol/ipratropium with annual costs per patient €120, 10.2% -
tiotropium with €606.2 annually, 9.1% - fenoterol with €103.3, 7.9% - salbutamol
with €27.5, 7.2% - fluticazone/salmeterol with €185, 6.8% - theophylline with €48.7,
2% - budesonide/formoterol €187.5 per patient annually. Therefore, in 2009 in
Ukraine the expenditures for basis treatment of 336,218 COPD patients’ with
fenoterol/ipratropium, tiotropium, fenoterol, salbutamol, fluticazone/salmet-
erol, theophylline budesonide/formoterol were €22,916,618.88, €20,789,165.86,
€3,160,550.07, €730,433.61, €4,478,423.76, €1,113,419.53, €1,260,817.50, respec-
tively. Moreover, the total basis medications costs in 2009 could be
€54,449,429.20 (€161.94 per patient). CONCLUSIONS: The study results showed
that basis medication costs per COPD patient in Ukraine could correspond with
costs in several EU countries. And we need to provide comparative cost studies for
medications reimbursement-system creation.
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IDENTIFYING THE PATIENT POPULATION WHERE TREATMENT OF SEVERE
ALLERGIC ASTHMA WITH OMALIZUMAB (XOLAIR®) EXHIBITS OPTIMAL COST-
EFFECTIVENESS IN AUSTRALIA
Tilden D1, Cottrell S1, Tocchini L1, Frenzel C2, Bonney MA2
1THEMA Consulting Pty Ltd, Pyrmont, NSW, Australia, 2Novartis Pharmaceuticals Australia,
North Ryde, NSW, Australia
OBJECTIVES: In Australia omalizumab (OM) is indicated for moderate-to-severe
allergic asthma. Two randomised controlled trials conducted in patients with se-
vere asthma compared optimised asthma therapy (OAT) (includes maximal in-
haled therapy) versus OMOAT. This analysis was to identify a patient subgroup in
which clinical need, comparative costs and effectiveness of OM is greatest.
METHODS: A Markov model incorporating local treatment algorithms and data
from the trials was developed. Patient subgroups were defined according to base-
line use of maintenance oral corticosteroids (MOCS), Asthma Control Question-
naire (ACQ-5) and Asthma Quality-of-Life Questionnaire (AQLQ) scores, FEV&rtf-
inf-start;1&rtf-inf-end;, exacerbation history and combinations of these. Costs and
effectiveness of OMOAT were compared with OAT alone. OM was continued only
while patients exhibited treatment response. Various definitions of response were
examined to optimise continuation criteria. Model parameters included: clinically
significant asthma exacerbations; hospital admissions; emergency visits; change
in MOCS dose; impact of MOCS on risk of certain chronic conditions; ACQ-5, AQLQ
and EQ5D utility index scores. The model estimated numbers of clinically signifi-
cant severe asthma exacerbations, deaths, life-years and QALYs gained due to OM.
RESULTS: OMOAT showed optimal cost-effectiveness in patients uncontrolled
on or intolerant to MOCS, with a baseline ACQ-5 2.0 or AQLQ 5.0. Response for
OM continuation was optimally defined as a reduction in ACQ-5 0.5 or 25%
reduction in MOCS dose without deterioration in ACQ-5. These patients benefitted
most from OM because they had severe disease, and were able to reduce exacer-
bations and MOCS dose and associated MOCS risks. The low baseline AQLQ score
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